These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 19275520)

  • 1. Synthesis of quinazolines as tyrosine kinase inhibitors.
    Srivastava SK; Kumar V; Agarwal SK; Mukherjee R; Burman AC
    Anticancer Agents Med Chem; 2009 Mar; 9(3):246-75. PubMed ID: 19275520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking quinazoline as a general support-Nog to design potent and selective kinase inhibitors: application to FMS-like tyrosine kinase 3.
    Li WW; Chen JJ; Zheng RL; Zhang WQ; Cao ZX; Yang LL; Qing XY; Zhou LX; Yang L; Yu LD; Chen LJ; Wei YQ; Yang SY
    ChemMedChem; 2010 Apr; 5(4):513-6. PubMed ID: 20140937
    [No Abstract]   [Full Text] [Related]  

  • 4. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
    Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
    Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X; Lv Y; Liu P; Li Z; Hu L; Zeng C; Yang L
    Bioorg Med Chem Lett; 2016 Mar; 26(6):1571-1575. PubMed ID: 26879314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
    Li DD; Fang F; Li JR; Du QR; Sun J; Gong HB; Zhu HL
    Bioorg Med Chem Lett; 2012 Sep; 22(18):5870-5. PubMed ID: 22901387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer.
    Choudhary S; Doshi A; Luckett-Chastain L; Ihnat M; Hamel E; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2021 Apr; 35():116061. PubMed ID: 33647840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, Synthesis, and Antitumor Activity of Novel Quinazoline Derivatives.
    Wang L; Li P; Li B; Wang Y; Li J; Song L
    Molecules; 2017 Sep; 22(10):. PubMed ID: 28956845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
    Das D; Hong J
    Eur J Med Chem; 2019 May; 170():55-72. PubMed ID: 30878832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer.
    Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S
    Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Unusual Binding Model of the Methyl 9-Anilinothiazolo[5,4-f] quinazoline-2-carbimidates (EHT 1610 and EHT 5372) Confers High Selectivity for Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases.
    Chaikuad A; Diharce J; Schröder M; Foucourt A; Leblond B; Casagrande AS; Désiré L; Bonnet P; Knapp S; Besson T
    J Med Chem; 2016 Nov; 59(22):10315-10321. PubMed ID: 27766861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents.
    Yassen AS; Elshihawy HE; Said MM; Abouzid KA
    Chem Pharm Bull (Tokyo); 2014; 62(5):454-66. PubMed ID: 24789927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
    Hou W; Ren Y; Zhang Z; Sun H; Ma Y; Yan B
    Bioorg Med Chem; 2018 May; 26(8):1740-1750. PubMed ID: 29523467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of some new 2,4,6-trisubstituted quinazoline EGFR inhibitors as targeted anticancer agents.
    Allam HA; Aly EE; Farouk AKBAW; El Kerdawy AM; Rashwan E; Abbass SES
    Bioorg Chem; 2020 May; 98():103726. PubMed ID: 32171987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors.
    Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity study of quinazoline derivatives leading to the discovery of potent EGFR-T790M inhibitors.
    Zhang L; Yang Y; Zhou H; Zheng Q; Li Y; Zheng S; Zhao S; Chen D; Fan C
    Eur J Med Chem; 2015 Sep; 102():445-63. PubMed ID: 26310890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
    Zeinyeh W; Esvan YJ; Nauton L; Loaëc N; Meijer L; Théry V; Anizon F; Giraud F; Moreau P
    Bioorg Med Chem Lett; 2016 Sep; 26(17):4327-9. PubMed ID: 27469128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, biological evaluation and docking study of novel quinazoline derivatives as EGFR-TK inhibitors.
    Jin H; Wu BX; Zheng Q; Hu CH; Tang XZ; Zhang W; Rao GW
    Future Med Chem; 2021 Apr; 13(7):601-612. PubMed ID: 33685233
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
    Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
    Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of tumor cell growth and angiogenesis by 7-aminoalkoxy-4-aryloxy-quinazoline ureas, a novel series of multi-tyrosine kinase inhibitors.
    Ravez S; Barczyk A; Six P; Cagnon A; Garofalo A; Goossens L; Depreux P
    Eur J Med Chem; 2014 May; 79():369-81. PubMed ID: 24747748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.